ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. (August 2017)

• Record Type: Journal Article
• Authors: Fermé, Christophe; Thomas, José; Brice, Pauline; Casasnovas, Olivier; Vranovsky, Andrej; Bologna, Serge; Lugtenburg, Pieternella J.; Bouabdallah, Réda; Carde, Patrice; Sebban, Catherine; Eghbali, Houchingue; Salles, Gilles; van Imhoff, Gustaaf W.; Thyss, Antoine; Noordijk, Evert M.; Reman, Oumédaly; Lybeert, Marnix L.M.; Janvier, Maud; Spina, Michele; Audhuy, Bruno; Raemaekers, John M.M.; Delarue, Richard; Anglaret, Bruno; de Weerdt, Okke; Marjanovic, Zora; Tersteeg, Robbert J.H.A.; de Jong, Daphne; Brière, Josette; Henry-Amar, Michel
• Is Part Of: European journal of cancer. Volume 81(2017)
• Page Start: 45
• Page End: 55
• Publication Date: 2017-08
• Subjects: Hodgkin lymphoma -- Early stage -- Chemotherapy -- Radiotherapy -- Treatment efficacy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.05.005
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Purpose: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584 ). Patients and methods: Patients aged 15–70 years with untreated supradiaphragmatic HL with at least one risk factor (age ≥ 50, involvement of 4–5 nodal areas, mediastinum/thoracic ratio ≥ 0.35, erythrocyte sedimentation rate (ESR) ≥ 50 without B-symptoms or ESR ≥ 30 and B-symptoms) were eligible for the randomised, open label, multicentre, non-inferiority H9-U trial. The limit of non-inferiority was set at 10% for the difference between 5-year event-free survival (EFS) estimates. From October 1998 to September 2002, 808 patients were randomised to receive either the control arm 6-ABVD-IFRT (n = 276), or one of the two experimental arms: 4-ABVD-IFRT (n = 277) or 4-BEACOPPbaseline -IFRT (n = 255). Results: Results in the 4-ABVD-IFRT (5-year EFS, 85.9%) and the 4-BEACOPPbaseline -IFRT (5-year EFS, 88.8%) were not inferior to 6-ABVD-IFRT (5-year EFS, 89.9%): difference of 4.0% (90%CI, -0.7%–8.8%) and of 1.1% (90%CI, -3.5%–5.6%) respectively. The 5-year overall survival estimates were 94%, 93%, and 93%, respectively. Patients treated with combined modality treatment chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vincristine (Oncovin), cyclophosphamide, procarbazine, etoposide and prednisone (BEACOPP)baseline more often developed serious adverse events requiring supportive measures and hospitalisation compared with patients receiving the chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD). Conclusions: The trial demonstrates that 4-ABVD followed by IFRT yields high disease control in patients with early-stage HL and risk factors responding to chemotherapy. Although non-inferior in terms of efficacy, four cycles of BEACOPPbaseline were more toxic than four or six cycles of ABVD. Highlights: 4 cycles of ABVD and IFRT 30Gy not inferior to 6-ABVD-IFRT in terms of efficacy. 4 cycles of BEACOPPbaseline have similar efficacy but more toxic than 4–6 ABVD. 4 cycles of ABVD is reference chemotherapy in early-stage HL with risk factors.